Johnson & Johnson (NYSE:JNJ) Stock Holdings Lifted by Exane Derivatives

Exane Derivatives lifted its position in Johnson & Johnson (NYSE:JNJGet Rating) by 87.9% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 10,612 shares of the company’s stock after buying an additional 4,965 shares during the quarter. Johnson & Johnson makes up about 1.1% of Exane Derivatives’ holdings, making the stock its 18th largest holding. Exane Derivatives’ holdings in Johnson & Johnson were worth $1,883,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Patron Partners LLC boosted its holdings in shares of Johnson & Johnson by 12.7% during the first quarter. Patron Partners LLC now owns 6,625 shares of the company’s stock worth $1,174,000 after purchasing an additional 747 shares during the period. Palisade Capital Management LLC NJ boosted its holdings in shares of Johnson & Johnson by 0.3% during the first quarter. Palisade Capital Management LLC NJ now owns 93,141 shares of the company’s stock worth $16,507,000 after purchasing an additional 250 shares during the period. Lmcg Investments LLC acquired a new stake in shares of Johnson & Johnson during the first quarter worth approximately $12,462,000. Capital Wealth Planning LLC boosted its holdings in shares of Johnson & Johnson by 14.0% during the first quarter. Capital Wealth Planning LLC now owns 916,575 shares of the company’s stock worth $162,445,000 after purchasing an additional 112,890 shares during the period. Finally, Tandem Investment Advisors Inc. boosted its holdings in shares of Johnson & Johnson by 4.8% during the first quarter. Tandem Investment Advisors Inc. now owns 326,505 shares of the company’s stock worth $57,867,000 after purchasing an additional 15,003 shares during the period. 68.59% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

JNJ has been the subject of several research reports. UBS Group decreased their price target on shares of Johnson & Johnson from $185.00 to $180.00 in a report on Thursday, July 21st. SVB Leerink reduced their target price on shares of Johnson & Johnson from $200.00 to $194.00 in a research note on Wednesday, July 20th. Wells Fargo & Company lifted their target price on shares of Johnson & Johnson from $190.00 to $195.00 and gave the company an “overweight” rating in a research note on Wednesday, July 13th. Morgan Stanley reduced their target price on shares of Johnson & Johnson from $174.00 to $173.00 and set an “equal weight” rating for the company in a research note on Monday, September 12th. Finally, Citigroup reduced their target price on shares of Johnson & Johnson from $205.00 to $201.00 in a research note on Wednesday, July 20th. Four research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus target price of $189.78.

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock opened at $163.28 on Thursday. The firm has a fifty day simple moving average of $168.25 and a 200-day simple moving average of $174.16. The company has a current ratio of 1.42, a quick ratio of 1.17 and a debt-to-equity ratio of 0.37. Johnson & Johnson has a 1-year low of $155.72 and a 1-year high of $186.69. The stock has a market capitalization of $429.29 billion, a price-to-earnings ratio of 23.77, a PEG ratio of 2.97 and a beta of 0.61.

Johnson & Johnson (NYSE:JNJGet Rating) last issued its quarterly earnings data on Tuesday, July 19th. The company reported $2.59 earnings per share for the quarter, topping analysts’ consensus estimates of $2.57 by $0.02. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.14%. The business had revenue of $24.02 billion during the quarter, compared to analysts’ expectations of $23.85 billion. During the same period in the previous year, the company earned $2.48 earnings per share. Johnson & Johnson’s revenue for the quarter was up 3.0% on a year-over-year basis. On average, sell-side analysts expect that Johnson & Johnson will post 10.7 earnings per share for the current year.

Johnson & Johnson declared that its Board of Directors has initiated a share buyback program on Wednesday, September 14th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the company to buy up to 1.2% of its shares through open market purchases. Shares buyback programs are typically a sign that the company’s management believes its stock is undervalued.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd were given a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a yield of 2.77%. The ex-dividend date of this dividend was Monday, August 22nd. Johnson & Johnson’s dividend payout ratio (DPR) is currently 65.79%.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Articles

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.